A Phase 1 interventional study of ABBV-1042 and Placebo in Healthy Volunteer, sponsored by AbbVie. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-22.
Sponsored by AbbVie · Phase 1, Interventional, and Basic science
This study will assess the adverse events, tolerability, and how oral ascending doses of ABBV-1042 moves through the body of healthy adult participants.
AbbVie is the lead sponsor of 953 studies on the registry; 136 are open to participants now.
Of its 350 completed or terminated interventional studies of FDA-regulated products, 210 (60%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Participants will receive an oral dose of ABBV-1042 or placebo on day 1.
Drug: ABBV-1042 · Drug: Placebo
Participants will receive an oral dose of ABBV-1042 or placebo on day 1.
Drug: ABBV-1042 · Drug: Placebo
Participants will receive an oral dose of ABBV-1042 or placebo on day 1.
Drug: ABBV-1042 · Drug: Placebo
Participants will receive an oral dose of ABBV-1042 or placebo on day 1.
Drug: ABBV-1042 · Drug: Placebo
Participants will receive an oral dose of ABBV-1042 or placebo on day 1.
Drug: ABBV-1042 · Drug: Placebo
Participants will receive an oral dose of ABBV-1042 or placebo on day 1.
Drug: ABBV-1042 · Drug: Placebo
Oral Solution
Oral Solution
Number of Participants Experiencing Adverse Events
An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.
Time frame: Up to approximately 32 days
Number of Participants with Abnormal Change From Baseline in Vital Sign Measurements
Number of participants with abnormal change from baseline in vital sign measurements like systolic and diastolic blood pressure will be assessed.
Time frame: Up to approximately 3 days
Change from Baseline in Columbia-Suicide Severity Rating Scale (C-SSRS)
The C-SSRS is a clinician-rated instrument that reports the severity of both suicidal ideation and behavior, with a higher score denoting more severe suicidal ideation and behavior.
Time frame: Up to approximately 3 days
Number of Participants with Abnormal Change in Physical Examinations
Number of participants with abnormal change in physical examinations in areas like cardiovascular, respiratory, and neurological systems will be assessed.
Time frame: Up to approximately 3 days
Number of Participants with Change from Baseline in Electrocardiogram (ECG)
12-lead resting ECG will be recorded.
Time frame: Up to approximately 3 days
Number of Participants with Abnormal Change in Clinical Laboratory Test Results Like Hematology will be Assessed
Number of participants with abnormal change in clinical laboratory test results like hematology will be assessed.
Time frame: Up to approximately 3 days
Maximum Plasma Concentration (Cmax) of ABBV-1042
Cmax of ABBV-1042
Time frame: Up to approximately 3 days
Time to Cmax (Tmax) of ABBV-1042
Tmax of ABBV-1042
Time frame: Up to approximately 3 days
Apparent terminal phase elimination constant (β) of ABBV-1042
β of ABBV-1042
Time frame: Up to approximately 3 days
Terminal Phase Elimination Half-Life (t1/2) of ABBV-1042
t1/2 of ABBV-1042
Time frame: Up to approximately 3 days
Area under the plasma concentration-time curve from time 0 until the last measurable concentration (AUCt) of ABBV-1042
AUCt of ABBV-1042
Time frame: Up to approximately 3 days
Area under the plasma concentration-time curve from time 0 to infinity (AUCinf) of ABBV-1042
AUCinf of ABBV-1042
Time frame: Up to approximately 3 days
Plan to share: No
No publications or documents are linked to this record.
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
AbbVie